Skip to content
Taxonomy
Development of Treatments for CMT2D
Professor Robert Burgess and his team at The Jackson Laboratory Read More
CMTA Updates List of Neurotoxic Meds Potentially More Hazardous to CMT Patients
The Charcot-Marie-Tooth Association (CMTA) announced the results of a review Read More
Development of Advanced Research Diagnostic Capabilities for the CMT Community
CMT is a genetic disease caused by distinct changes in Read More
Studying Neurodegeneration in CMT1X Mouse Model
In people with CMT1X cell-to-cell communication within the peripheral nervous Read More
Establishing gene therapy strategies for CMT2E
CMT2E is caused by dominant or recessive mutations in the Read More
CMTA to attend the annual BIO partnering conference in Boston
The CMTA is a global leader in the acceleration of Read More
CMTA Adds Science Writer Kenneth Raymond to Team
On April 17, 2023, the Charcot-Marie-Tooth Association welcomed Kenneth Raymond Read More
CMTA Partnering is Open for Business
The CMTA is a global leader in the acceleration of Read More
CMTA Funds Preclinical Work on Modulating Unfolded Protein Response in CMT1B Mice
The Charcot-Marie-Tooth (CMT) Association announced a $33,000 grant on April Read More
Gene Therapy Advances for CMT4J, CMT4A and GAN
Steven Gray, PhD, an Associate Professor at the University of Read More
